FindTrial
Sign In

Clinical study to evaluate the effect of a unani formulation of tila in melasma

A clinical study of kalaf(melasma) with therapeutic evaluation of tila tukhm-e-jarjir (Eruca sativa linn.)and tukhm-e-turb(Raphanus sativus var.longipinnatus) in its management ; A block randomised single blind standard controlled study - nil

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/02/062478
Enrollment
48
Registered
2024-02-09
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L811- Chloasma

Interventions

Intervention1: Tila (Liniment): Tila prepared from Tukhm-e-jarjir(Eruca Sativa linn.) and Tukhm-e-Turb(Raphanus sativus var.Longipinnatus) along with sirka angoori will be given to the patient for app

Sponsors

Central Council for Research in Unani Medicine New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Clinically diagnosed patients of Kalaf. Patients irrespective of gender. Patients in the age group of 18 to 60 years

Exclusion criteria

Exclusion criteria: Known cases of skin allergy or sensitivity as revealed by history and clinical examintaion. Pregnant and Lactating Women and Patients on Oral Contraceptives. Diseases requiring long term treatments (Including Uncontrolled Diabetes Mellitus, Cardiovascular Diseases, Chronic Renal Diseases, Chronic Liver Diseases) Diagnosed by History of patient and Clinical Examination. Unwillingness or inability to fill the protocol. Patients who fail to give the informed consent.

Design outcomes

Primary

MeasureTime frame
Brown and Black Pigmentation measure by physicians assessment scale. Irregular, sharp, black and brown hyperpigmented macules measure by Likert Scale.Timepoint: day 0, day 7, day 14 , day 21 and day 29—

Secondary

MeasureTime frame
photographs of the hyperpigmented macules or lesion. Identity and also the photographs clicked will be placed in such a manner that his or her eyes are not revealed and hence the confidentiality will be maintained. Melasma Area Severity Index (MASI)Timepoint: day 0 and day 29—

Countries

India

Contacts

Public ContactDr Faheem Akhtar

Regional Research Institute of Unani Medicine

sheeraz.rrium@gmail.com9797750472

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026